Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on April 23, 2025
Orion-konsernin osavuosikatsaus tammi–maaliskuu 2025
GlobeNewswire
·
April 23, 2025
ORION OYJ OSAVUOSIKATSAUS 1–3/2025 23.4.2025 klo 12:00 Orion-konsernin osavuosikatsaus tammi–maaliskuu 2025 Tammi–maaliskuu 2025 lyhyesti Liikevaihto oli 354,6 miljoonaa euroa (308,5 miljoonaa euroa 1–3/2024) Liikevoitto oli 77,9 (56,0) miljoonaa euroa …
Point of Care Hematology Diagnostics Market to Reach $3.0 Bn by 2027 in the short run and $3.6 Bn by 2030 Globally, at 5.8% CAGR: Allied Market Research
GlobeNewswire
·
April 23, 2025
Wilmington, Delaware, April 23, 2025 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, “Point of Care Hematology Diagnostics Market - Global Opportunity Analysis and Industry Forecast, 2024-2030", valued at $2.4 billion in 2023, is …
Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers
GlobeNewswire
·
April 23, 2025
Ingelheim, Germany and Amsterdam, the Netherlands, 23 April 2025 – Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into a research collaboration and global …
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS
GlobeNewswire
·
April 23, 2025
For media and investors only Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome …
Cytovation Raises US$6m to Advance Phase 2 Development of CY-101 in Adrenocortical Carcinoma to First Clinical Readouts
GlobeNewswire
·
April 23, 2025
New funds provided largely by existing investors, led by Sandwater Phase 2 trial to be delivered through novel agreement between Cytovation, Cancer Research UK and the Norwegian Cancer Society New preclinical data highlighting potential of CY-101 in ACC …
Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers
GlobeNewswire
·
April 23, 2025
INGELHEIM, Germany and AMSTERDAM, April 23, 2025 (GLOBE NEWSWIRE) -- Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into a research collaboration and …
Antag Therapeutics expands senior team to support clinical progress
GlobeNewswire
·
April 23, 2025
Copenhagen, Denmark, 23 April 2025 – Antag Therapeutics (“Antag” or “the Company”), a biopharmaceutical company pioneering novel treatments for obesity, today announces the appointment of three new hires to support the Company’s next phase of growth …
Codex Labs Bia Ultra-Hydrating Soothing Lotion Is Awarded Seal of Acceptance from National Eczema Association and Microbiome-Friendly Certification from MyMicrobiome
GlobeNewswire
·
April 23, 2025
San Jose, CA, USA, April 23, 2025 (GLOBE NEWSWIRE) -- Codex Labs, a Silicon Valley skintech company, announced that its Bia Ultra-Hydrating Soothing Lotion, the European version of its US Bia over-the-counter (OTC) Bia Eczema Relief Lotion has been awarded …
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
GlobeNewswire
·
April 23, 2025
Five abstracts accepted for poster presentations WARMINSTER, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today …
VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies
GlobeNewswire
·
April 23, 2025
VERAXA’s Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug Conjugate ("ADC") and Bispecific T-cell Engager ("TCE") Candidates, with Strong and Differentiated Clinical …
ProDentim Complaints & Side Effects (EXPOSED) Investigative Consumer Report Examines Scientific Claims About ProDentim!
GlobeNewswire
·
April 23, 2025
AUSTIN, Texas, April 22, 2025 (GLOBE NEWSWIRE) -- ProDentim is a dental probiotic formula that fosters healthy teeth and gums by building a balanced ecosystem within the mouth. It addresses the root cause of oral conditions and eliminates pathogenic …
CMVC adquiere Orlando Medical Institute y expande su portafolio educativo en el campo de salud con programas de paramédico y atención médica de emergencia
GlobeNewswire
·
April 23, 2025
ORLANDO, Florida, April 22, 2025 (GLOBE NEWSWIRE) -- Compu-Med Vocational Careers (CMVC), anuncia la adquisición de Orlando Medical Institute (OMI). Esta adquisición estratégica acelera la expansión de los programas educativos en salud de CMVC al agregar …
浩鼎将在AACR发表七篇海报论文
GlobeNewswire
·
April 23, 2025
台北讯, April 23, 2025 (GLOBE NEWSWIRE) -- 浩鼎生技（TPEx: 4174.TWO）今日首次公布其自主开发的次世代GlycOBI®技术平台所开发抗体药物偶联体（ADC）OBI-902的非临床数据，显示其具备优异的药物动力学特性，并在多种具挑战性的实体肿瘤动物模型中展现持续的抗肿瘤活性，且优于目前已上市的TROP2 ADC，显示OBI-902具备成为同类最佳ADC的潜力。OBI-992则为采用半胱氨酸连接技术的TROP2靶向ADC，其耐药性特征异于现有同类产品。 在本次 …
浩鼎將在AACR發表七篇海報論文
GlobeNewswire
·
April 23, 2025
台北電, April 23, 2025 (GLOBE NEWSWIRE) -- 台灣浩鼎生技（TPEx: 4174. TWO）今首度公布其自主開發的次世代 GlycOBI® 技術平台所開發抗體藥物複合體（ADC）OBI-902 非臨床數據，具有優異的藥物動力學特性，以及在多種具挑戰性的實體腫瘤動物模型中展現持續的抗腫瘤活性，亦證明優於目前已上市的 TROP2 ADC，證明OBI-902 具有成為同類最佳ADC的潛力。OBI-992 為半胱胺酸連接技術的 TROP2 靶向 ADC，其耐藥性特徵有異於目前同類的 …
OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science
GlobeNewswire
·
April 23, 2025
TAIPEI, Taiwan, April 23, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174. TWO) today announced nonclinical data for OBI-902, a potential best-in-class anti-TROP2 ADC developed using the next generation proprietary GlycOBI® technologies. OBI-902 …
Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025
GlobeNewswire
·
April 23, 2025
Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data during the 2025 Digestive Disease Week (DDW) meeting from …